WA
ALXN

Whitebox Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

Whitebox Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-36,060
Closed -$6.67M – 457
2014
Q4 		$6.67M Sell
36,060
-48,765
-57% -$9.04M 0.27% 79
2014
Q3 		$14.1M Sell
84,825
-9,375
-10% -$1.54M 0.55% 41
2014
Q2 		$14.7M Buy
+94,200
New +$14.9M 0.58% 46

Other funds holding ALXN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Whitebox Advisors's ALXN Position: Q1 2015 in Review

Whitebox Advisors sold out of Alexion Pharmaceuticals (ALXN) in Q1 2015, closing a stake of 36,060 shares — an estimated $6.67M sold.

Whitebox Advisors first reported a position in ALXN in Q2 2014 and held it in 3 quarters. The position peaked at $14.7M in Q2 2014. 566 funds tracked by Wall St. Rank hold ALXN as of Q1 2015.

  • Whitebox Advisors reported no remaining Alexion Pharmaceuticals position as of Q1 2015 after selling out during the quarter.
  • Whitebox Advisors sold 36,060 Alexion Pharmaceuticals shares in Q1 2015, an estimated $6.67M.
  • Whitebox Advisors first reported a position in Alexion Pharmaceuticals in Q2 2014 and held it in 3 quarters.
  • Whitebox Advisors's Alexion Pharmaceuticals position peaked at $14.7M in Q2 2014.
  • 566 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2015.

Based on Whitebox Advisors's 13F filing for Q1 2015, filed 12 May 2015.